South and Central America Cardiometabolic Diseases Market

Market Introduction

The cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are some of the symptoms. Individuals suffering from cardiometabolic syndrome are prone to several other life-threatening diseases such as type 2 diabetes, stroke, coronary artery disease (CAD), cardiovascular disease (CVD), and many others.

Moreover, the increasing prevalence of cardiometabolic diseases is expected to bolster the market growth during the forecast period. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) limits the growth of the South and Central America cardiometabolic diseases market.

Brazil, Argentina, Uruguay, Chile, Peru, Colombia is concerned by the second wave of corona infection. Amongst which Brazil has registered the majority of the deaths. It is anticipated that the region will likely force a second lockdown, which will ultimately hamper the healthcare industry in the area. There have been intensive attempts to explore drug therapy to prevent and treat SARS-CoV-2 infection during this COVID-19 pandemic. Thus, the ongoing clinical studies regarding cardiometabolic diseases market for COVID in the region is likely to favor the growth of the market. 

Market Overview and Dynamics

The South and Central America cardiometabolic diseases market is projected to reach US$ 10,295.5 million by 2028 from US$ 8,472.6 million in 2021; it is anticipated to grow at a CAGR of 2.8% from 2021 to 2028. The healthcare industry's transformation from one-size-fits-all to a targeted approach is expanding the demand for personalized medicines. Due to advances in personalized medicine based on individual genetic structure, these medicines are steadily becoming the trademark of chronic disease treatments. The increasing research on the integration of personalized treatment for chronic diseases is opening new therapeutic avenues. Pharmaceutical giants have also been exploring personalized treatment options for CMDs. Recently, Novartis received rights from Akcea Therapeutics to develop and commercialize TQJ230, an investigational agent for targeted cardiovascular therapy. Millions of people have elevated lipoprotein (a), an independent inherited CVD risk factor that cannot be effectively addressed by diet and other lifestyle changes. If approved, TQJ230 could be the first-in-class treatment, explicitly targeting elevated Lp(a). Also, advancements in AI and data analytics are supporting disease management development by personalizing medicines to provide precise intervention. These factors have increased the growth trajectory of the South and Central America cardiometabolic diseases market.

Key Market Segments

In terms of type, the cardiovascular disease segment accounted for the largest share of the South and Central America cardiometabolic diseases market in 2020. In terms of treatment, the ACE inhibitors segment accounted for the largest share of the South and Central America cardiometabolic diseases market in 2020. In terms of dosage, the tablet segment accounted for the largest share of the South and Central America cardiometabolic diseases market in 2020. In terms of route of administration, the oral segment accounted for the largest share of the South and Central America cardiometabolic diseases market in 2020. In terms of end user, the hospital segment accounted for the largest share of the South and Central America cardiometabolic diseases market in 2020. Further, based on distribution channel, the hospital pharmacy segment held the largest market share in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the cardiometabolic diseases market in South and Central America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Bayer AG, Novartis AG, Kowa Company, Ltd., Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, and AstraZeneca.

Reasons to Buy Report

• To understand the South and Central America cardiometabolic diseases market landscape and identify market segments that are likely to guarantee a strong return
• To comprehend the ever-changing market landscape and stay ahead in competition
• To efficiently plan merger and acquisition, and partnership deals in the South and Central America cardiometabolic diseases market by identifying segments with the most promising probable sales
• To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
• To obtain market revenue forecast of the South and Central America cardiometabolic diseases market based on various segments for the period 2021–2028

SOUTH AND CENTRAL AMERICA CARDIOMETABOLIC DISEASES MARKET SEGMENTATION

By Type

• Cardiovascular disease (CVD)
• Type 2 diabetes
• Hypertension
• Obesity

By Treatment

• ACE inhibitors
• Diuretics
• Glucophage
• Others

By Dosage

• Tablet
• Injection

By Route of Administration

• Oral
• Intravenous 

By End Users

• Hospital
• Clinic
• Homecare settings

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Country

• South and Central America
• Brazil
• Argentina
• Rest of South and Central America

Companies Mentioned

• Bayer AG                         
• Novartis AG                   
• Boehringer Ingelheim International Gmbh
• Novo Nordisk A/S       
• AstraZeneca
• Kowa Company, Ltd.                 

South and Central America Cardiometabolic Diseases Market Strategic Insights

South and Central America Cardiometabolic Diseases Market Report Highlights

South and Central America Cardiometabolic Diseases Market Country and Regional Insights